UCB is a global biopharma focused on severe diseases in two therapeutic areas: central nervous system and immunology operations.
The company is listed on the Euronext Brussels Stock Exchange and has its headquarters in Brussels, Belgium. It employs more than 8,500 people in more than 40 countries.
Financial Data
-
31st Dec 20 Source: CRO
- €0.1 million turnover
-
€0.3 million
profit - 0 employees
-
31st Dec 19 Source: CRO
- €1.1 million turnover
-
-€0.6 million
profit - 0 employees
- 12 more years available »
Ranking
By Turnover
(€0.1 million)- 962nd in Top Companies
- 94th in Health
- 80th in Pharma
By Employees
(0)- 1030th in Top Companies
- 93rd in Health
- 78th in Pharma
-
- 0
- €0.1 million
Employees
- Claire Brading Country Manager
Latest News
- May 24 Harsh winter may compel Europe to ration gas, warns International Energy Agency
- May 24 Hungary and Poland hold up EU decisions on oil and corporate tax
- May 24 Over 700 objections lodged against €466m Dundrum apartment ‘concrete jungle’
- May 24 Stripe unveils new third party app marketplace
- May 24 Shares in UK energy companies slide over windfall tax fears